Pemetrexed (MTA)

A guanine-derived ANTINEOPLASTIC AGENT that functions as a NUCLEIC ACID SYNTHESIS INHIBITOR through its binding to, and inhibition of, THYMIDYLATE SYNTHASE.

Also Known As:

MTA; LY231514; Alimta; LY 231,514; LY 231514; LY-231,514; LY-231514; N-(4-(2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; Pemetrexed Disodium; 231,514, LY; 231514, LY; Disodium, Pemetrexed; L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-

Networked: 3680 relevant articles (480 outcomes, 1229 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Arnold, L Eugene: 47 articles (02/2022 - 05/2002)
2.	Swanson, James M: 36 articles (02/2022 - 05/2002)
3.	Hechtman, Lily: 36 articles (01/2022 - 05/2002)
4.	Scheltens, Philip: 36 articles (01/2020 - 07/2004)
5.	Hinshaw, Stephen P: 34 articles (02/2022 - 01/2002)
6.	Molina, Brooke S G: 34 articles (02/2022 - 11/2004)
7.	Jensen, Peter S: 28 articles (02/2022 - 05/2002)
8.	Reck, Martin: 28 articles (10/2020 - 04/2005)
9.	Ahn, Myung-Ju: 28 articles (01/2020 - 01/2009)
10.	Yamamoto, Nobuyuki: 25 articles (09/2022 - 07/2008)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/15/2021 - "Pemetrexed is an important component of first line treatment in patients with non-squamous non-small cell lung cancer. " 02/01/2021 - "Pemetrexed has significant efficacy for some non-squamous non-small cell lung cancer cases, as demonstrated in the current case. " 02/01/2004 - "These data suggest that pemetrexed has significant activity in advanced non-small cell lung cancer and represents a new treatment option for patients with this disease." 11/01/2020 - "Our research hopes to develop a TS inhibitor that is more effective than the current first-line clinical treatment of pemetrexed (PTX) and provide a new reference for the clinical treatment of non-small cell lung cancer (NSCLC). " 07/01/2019 - "Pemetrexed has been shown to be effective in the treatment of advanced and metastatic nonsquamous nonsmall cell lung cancer. "
2.	Neoplasms (Cancer) 07/01/2011 - "The SPECT/CT studies confirmed the excellent tumor-to-background contrast of (67)Ga-radiofolate and the favorable reduction in kidney uptake (with improved imaging quality) resulting from pemetrexed administration. " 02/01/2020 - "Similarly, whereas high local tumor failure rate has been a major concern with RFA, MWA or microwave thermosphere ablation (MTA) have demonstrated significantly improved local tumor control due to homogenous tissue heating, ability to reach higher tissue temperatures, and less susceptible to the "heat-sink" effect. " 07/01/2014 - "Furthermore, the paucity of mitotic cells in patient tumors and lack of correlation of MTA efficacy with tumor proliferation rate provide strong impetus to re-examine the mechanistic basis of action of MTAs, with an eye toward interphase activities. " 10/01/2005 - "Phase II/III clinical trials have shown that pemetrexed is effective against various solid tumors. " 02/11/2011 - "Systemic MTA accumulation is implicated as the tumor-suppressive metabolite because MTDIA is effective for in vivo treatment of A549 MTAP(-/-) and H358 MTAP(+/+) tumors. "
3.	Adenocarcinoma of Lung 01/01/2015 - "We investigated the impact of the genetic polymorphisms on the therapeutic efficacy of pemetrexed in lung adenocarcinoma patients. " 01/01/2023 - "Pemetrexed-based immunochemotherapy represents an established standard of care as first line treatment for non-oncogenic driven metastatic non-small cell lung adenocarcinoma (NSCLC/ADC). " 01/01/2022 - "Furthermore, in a lung adenocarcinoma retrospective cohort (N = 72) from the published BATTLE2 clinical trial (NCT01248247), MTAPdef associates with an improved response rate to pemetrexed. " 09/01/2017 - "Survival of patients with advanced stage IIIB/IV lung adenocarcinoma has improved over the past decade, and is potentially associated with the use of EGFR TKI and pemetrexed." 04/01/2016 - "Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations."
4.	Malignant Mesothelioma 05/01/2012 - "In our institution, the MTA plus CDDP regimen was the first-line treatment, and the GEM plus CDDP regimen was the second-line treatment against peritoneal malignant mesothelioma. " 02/01/2007 - "Pemetrexed is active as first-line treatment of malignant pleural mesothelioma. " 01/01/2007 - "Efficacy of pemetrexed has been demonstrated in malignant pleural mesothelioma. " 04/15/2003 - "This phase II clinical study evaluated the efficacy of pemetrexed for the treatment of malignant pleural mesothelioma (MPM). " 11/01/2020 - "Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901."
5.	Mesothelioma 04/01/2013 - "Pemetrexed has been approved with an anti-mesothelioma drug and was confirmed to be effective for NSCLC. " 10/01/2009 - "Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: The Nancy Centre of Biological Resources' Mesothelioma Cohort." 11/01/2006 - "Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma." 12/01/2023 - "This was a cooperative group, single-arm, phase 2 trial enrolling patients with unresectable mesothelioma after progression on more than or equal to one pemetrexed-containing regimen. " 02/01/2018 - "F-FDG PET/CT and DCE-MRI studies carried out as part of the South West Area Mesothelioma Pemetrexed trial were used. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Platinum
3.	Carboplatin (JM8)
4.	Bevacizumab (Avastin)
5.	Gemcitabine
6.	Gefitinib (Iressa)
7.	Docetaxel (Taxotere)
8.	pembrolizumab
9.	ErbB Receptors (EGF Receptor)
10.	Folic Acid Antagonists

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Combined Modality Therapy
4.	Radiotherapy
5.	Adjuvant Chemotherapy